Reporting owner · CIK 0001053890
Debbane Raymond
Visual SEC Form 4 history across 2 companies, 13 transactions and 6 filings.
DIRLEXICON PHARMACEUTICALS, INC.
Open-market mix
100%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
For every open-market buy (Form 4 code P, acquisition A) in the selected window, we take the closing price on the transaction date and 90 calendar days later, then compute the percentage change. The figures shown are the simple average and median of those per-buy returns.
- Window follows the rest of the summary (all-history or last 3 months).
- Only buys with a resolved price context are counted.
- Includes both positive and negative outcomes; gains and losses net out at the per-buy level.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Dec 25
$0
Feb 26
$2.7M
Transaction texture
Ownership and ticket size
Average P/S size$340.3K
Median P/S size$123.8K
Direct9
Indirect4
Feb 25, 2026buy
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
buy at LEXICON PHARMACEUTICALS, INC. on Feb 25, 2026 valued at $2,980.
Review SEC filingLatest sale
No open-market insider sale is available.
Associated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| LXRX | DEBBANE RAYMOND | DIR | buy | 1.53M | $200M | P | +29.9% | 02/04 | 02/02 | |
| LXRX | DEBBANE RAYMOND | DIR | grant | 3.84M | $500M | A | +29.9% | 02/04 | 02/02 | |
| LXRX | DEBBANE RAYMOND | DIR | grant | 18.5M | $2.41B | A | — | +29.9% | 02/04 | 02/02 |
Debbane Raymond Insider Activity FAQ
SEC Form 4 context
Who is Debbane Raymond?
Debbane Raymond is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001053890.
Which companies has Debbane Raymond reported transactions for?
LEXICON PHARMACEUTICALS, INC., Scholar Rock Holding Corp
When was Debbane Raymond's latest insider buy?
buy at LEXICON PHARMACEUTICALS, INC. on Feb 25, 2026 valued at $2,980.
When was Debbane Raymond's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.